TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04026763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prostate biopsy
Description: standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR US Fusion Guided Prostate Biopsy
Description: Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy, Transperineal Ultrasound guided fusion prostate biopsy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR/TRUS Fusion Guided Prostate Biopsy
Description: TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
Study: NCT01152489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Buzzy
Description: Buzzy, the vibrating cold pack, is held in place with a velcro strap or pressed by caretaker or nurse immediately prior and during immunizations. The vibration is activated and the device remains in place during the shot, moving locations if multiple shots are given. Distraction cards with pictures on one side and questions on the other are shown to the child while the caretaker asks the finding and seeking questions on the back.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Buzzy: sham device
Description: The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
Study: NCT02022956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Study: NCT01146041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine 1.5 mg Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Rivastigmine 1.5 mg Capsules
Study: NCT03185104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
Study: NCT03106012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
Study: NCT04690257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trace Image and Coloring for Kids-Book (TICK-B)
Description: A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
Study: NCT02278991

Intervention type: DEVICE
Intervention: Lutonix Drug Coated Balloon
Description: Subject will receive treatment with the Lutonix Drug Coated Balloon
Study: NCT00082043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study: NCT00871572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: 4 capsules by mouth taken once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: 4 capsules by mouth taken once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: 4 capsules by mouth taken once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules by mouth once daily for 12 weeks
Study: NCT02330913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal esophagojejunostomy
Description: Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
Study: NCT00709124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)
Description: 60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
Study: NCT04137146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral Nerve Stimulation
Description: Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)
Study: NCT01236859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Neurontin®, Pfizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Neurontin®, Pfizer
Study: NCT00719862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo
Study: NCT03654274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
Study: NCT04522934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of pain neuroscience education. The latter was focused on the influence of psychosocial factors in the experience of pain, differences between acute and chronic pain and central-peripheral awareness.
Study: NCT00719862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15% azelastine hydrochloride Nasal Spray
Description: 0.15% azelastine hydrochloride 822 mcg
Study: NCT01287546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2875358
Description: Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2875358 + erlotinib
Description: Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2875358 at Part A highest dose
Description: Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2875358 at Part A highest dose + trametinib
Description: Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
Study: NCT03134924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's and Sexual Health [WASH]
Description: The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Standard of Care
Description: The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP.
Study: NCT01250756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7-pneumococcal conjugate vaccine (7vPnC)
Description: 0.5 mL per dose, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: diphtheria, tetanus, and acellular pertussis vaccine (DTaP)
Description: 0.5 mL per dose, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP
Description: 0.5 mL per dose, 4 doses
Study: NCT00209170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: Beating the Blues is a computerized cognitive behavioral therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beating the Blues
Description: Beating the Blues is a computerized cognitive behavioral therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A sugar pill taken as one to two tablets daily for 6 months.
Study: NCT04480931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Intervention Group
Description: Access to the mobile health application with exercise plans and education

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Educational Brochure
Description: An evidence-based educational brochure with general information about the benefits of physical activity during pregnancy
Study: NCT03579992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60-min isometric MyCI training
Description: EMG-controlled in-lab training with arm restrained for 60 minutes per session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 90-min isometric MyCI training
Description: EMG-controlled in-lab training with arm restrained for 90 minutes per session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 90-min movement MyCI training
Description: EMG-controlled in-lab training without restraint for 90 minutes per session
Study: NCT01481090

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture, Electro-Acupuncture
Description: Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
Study: NCT02162121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus: stimulating catheter
Description: Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infusion
Description: Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic infusion
Description: Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times a day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times a day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioids rescue analgesia
Description: Buprenorphine 0,2mg twice a day if VAS\>4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioids rescue analgesia
Description: Buprenorphine 0,2mg twice a day if VAS\>4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0,5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0,5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0,2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine 0,2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0,2mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulong, Pajunk, Germany.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulong, Pajunk, Germany.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous lumbar plexus: non-stimulating catheter
Study: NCT05227482

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Personalized dosimetry approach
Description: The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosimetry approach
Description: The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
Study: NCT04430946

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standardized test meal
Description: A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standardized test meal
Description: A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standardized test meal
Description: A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standardized test meal
Description: A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes
Study: NCT02022033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXA
Description: Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)
Study: NCT03539913

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic : Saccharomyces boulardii
Description: Treatment for 5 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic : Bacillus clausii
Description: Treatment for 5 days
Study: NCT01499901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral cochlear Implantation in sequential
Description: bilateral cochlear Implantation in sequential

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral cochlear Implantation in simultaneous
Description: bilateral cochlear Implantation in simultaneous
Study: NCT03949140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser hair removal
Description: Those who consent to participate in the study will be treated with up to 8 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
Study: NCT03398733

Intervention type: DEVICE
Group type: OTHER
Intervention: continuous positive airway pressure
Description: The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
Study: NCT03685487

Intervention type: PROCEDURE
Intervention: decolonization
Description: current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all

Intervention type: OTHER
Intervention: compliance questionnaire
Description: We asked if the patient has done the whole decolonization procedure
Study: NCT02251678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elimune Capsules
Description: 2 capsules BID for 28 days
Study: NCT04973410

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coronary Physiology
Description: Invasive coronary physiology measurements during diagnostic CAG with thermodilution method with the CoroFlow® (Coroventis, Uppsala, Sweden)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Coronary Physiology
Description: Invasive coronary physiology measurements during diagnostic CAG with thermodilution method with the CoroFlow® (Coroventis, Uppsala, Sweden)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 15O-H2O-PET scan
Description: Myocardial blood flow (MBF) measured with oxygen-15 (O-15) labelled water used as a tracer molecule with positron emission tomography (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 15O-H2O-PET scan
Description: Myocardial blood flow (MBF) measured with oxygen-15 (O-15) labelled water used as a tracer molecule with positron emission tomography (PET)
Study: NCT00109772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Two 5 mg capsules taken one time per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules taken one time per day
Study: NCT03159806

Intervention type: DEVICE
Intervention: Microdialysis sampling
Description: Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
Study: NCT00370877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIa
Description: The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients will recieve standard care for post partum hemorrhage according to current recommendations.
Study: NCT03748277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression
Description: Bilateral decompression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Bilateral decompression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PLIF
Description: Traditional open surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIS TLIF
Description: On the one side - Wiltse approach, on the other side - percutaneous

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screw Fixation
Description: Transpedicular Screw Fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screw Fixation
Description: Transpedicular Screw Fixation
Study: NCT01127295

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen, Letrozole, Anastrozole or Exemestane
Description: Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
Study: NCT01164592

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: adaptive servoventilation (ASV)
Description: Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
Study: NCT02516150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: injection of 50 micrograms of glucagon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: injection of 50 micrograms of glucagon
Study: NCT04970394

Intervention type: BEHAVIORAL
Intervention: Cervical Screening Reminder
Description: Verbal reminder and if seen face-to-face, a written appointment booking slip.
Study: NCT01188096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
Study: NCT04278482

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement, DHA or Placebo
Description: Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement, DHA or Placebo
Description: Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo
Study: NCT02742857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BQ-A Peptide Extract
Description: BQ-A Peptide Extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Mesenchymal Stem Cells

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Laser Therapy
Description: Transcranial Laser Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Median Nerve Stimulator
Description: Median Nerve Stimulator
Study: NCT02651792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine- propofol
Description: 1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidine- propofol
Description: 1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction